Jeffrey Kindler, the executive who was promoted from general counsel to chairman and chief executive officer of Pfizer Inc. four years ago, has suddenly retired at age 55.

Late Sunday New York-based Pfizer announced that Kindler was leaving and that the board of directors had chosen Ian Read, 57, head of the company’s global biopharmaceutical operations, to succeed him as CEO. The board said it would name a separate chairman in two weeks.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]